Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Allergan’s Botox Enters Phase III Clinical Trial for Major Depressive Disorder



The mid-stage trial evaluated the tolerability of two doses of Botox (30 units or 50 units) in female patients diagnosed with MDD.

Share this!

April 7, 2017 | by Sarah Hand, M.Sc.

Earlier this week, Dublin-based pharmaceutical company, Allergan, announced topline data from a Phase II clinical trial investigating the safety and efficacy of Botox to treat patients with Major Depressive Disorder (MDD). While the blockbuster drug was considered to be numerically superior in terms of efficacy, when compared to a placebo, the study team could not prove statistical significance.

The mid-stage trial evaluated the tolerability of two doses of Botox (30 units or 50 units) in female patients diagnosed with MDD. In all, 258 patients with severe MDD were enrolled in the trial, based on their scores on two major depression scales, the Hamilton Rating Scale for Depression and the Clinical Global Impressions Scale.

Patients were randomly assigned to receive a 30 or 50 unit dose of Botox, or a placebo. The study investigators measured the primary endpoint as the change in Montgomery-Asberg Depression Rating Scale (MADRS) total score from baseline to week six of the study.

According to Allergan, the 30 unit dose of Botox showed numerical superior efficacy in achieving the primary endpoint, compared to the placebo. Patients taking this dose showed an average treatment difference of -3.7 in the MADRS total score at week six of the study.

Patients taking the 50 unit dose of Botox did not show numerically superior efficacy over the placebo. Despite this, both doses were well tolerated in patients.

“We are encouraged by these data and the potential impact on adults with major depressive disorder,” said David Nicholson, Chief Research and Development Officer, Allergan. “Given our in-depth and extensive clinical trial experience in CNS including depression, we plan to move forward and develop a phase III program for a potential new treatment option for patients.”

Though Allergan did not report statistically significant results – the gold standard of showing efficacy over a placebo – the drugmaker has announced that Botox will be pushed forward into a Phase III clinical trial for MDD. While it’s not clear when this late-stage trial will commence, it’s likely that Allergan will only include the lower dose in the next phase.

Originally approved as a cosmetic product to reduce wrinkles on the face and neck, Botox has since been approved for a number of additional medical indications, including excessive perspiration, migraines and muscle stiffness. In 2016, global sales of Botox reached $2.8 billion, making it Allergan’s best seller.

Keywords:  Clinical Trial, Depression, Blockbuster


Share this with your colleagues!

Canadian Regulator Recalls Pie Shells Over E. Coli Contaminated Flour

April 28, 2017 - Multiple brands of pie and tart shells are being recalled in Canada after the flour used to manufacture them was linked to 28 cases of illness due to infection with E. coli O121.

Featured In: Food News

FDA Sends Warning Letters to Manufacturers of Fake Cancer Drugs

April 27, 2017 - The FDA is cracking down on the sale of illegal cancer drugs by sending warning letters to 14 US companies selling the unapproved products.

Featured In: Life Science News, Drug Safety News

Womb-Like Device Could Increase Survival of Premature Babies

April 27, 2017 - Researchers at the Children's Hospital of Philadelphia (CHOP) have developed a womb-like device which mimics the environmental conditions found inside the uterus.

Featured In: Life Science News, Medical Device News


What Medical Device Manufacturers Need to Know Before Developing a Biological Safety Evaluation


Technology Solutions for Late Phase Research: Optimising Real World Data Assets

Serialization for Late Starters – With Live Industry Research Results

Clinical Not All Antioxidants Are Created Equal: Astaxanthin, The Antioxidant Powerhouse

The New Gold Standards of IRT Delivery for Clinical Trials

Copyright © 2016-2017 Honeycomb Worldwide Inc.